



Statin Therapy for Patients With Cardiovascular Disease (SPC)

SPC Measure Description¹

Statin Therapy for Patients with Cardiovascular Disease: Assesses males 21–75 years of age and females 40–75 years of age who have clinical atherosclerotic cardiovascular disease (ASCVD) and who received and adhered to statin therapy.

Why is SPC Important?¹

Cardiovascular disease is the leading cause of death in the United States. It is estimated that 92.1 million American adults have one or more types of cardiovascular disease (Benjamin et al., 2017). People with diabetes also have elevated cardiovascular risk, thought to be due in part to elevations in unhealthy cholesterol levels. Having unhealthy cholesterol levels places people at significant risk for developing ASCVD.

Best Practices

- ✓ Educate members on the importance of statin medications and how it reduces cardiovascular risk for people with diabetes.
- ✓ Discuss any barriers members may have with getting prescriptions.
- ✓ Medication samples can skew measurements if given and there is a delay filling of the statin prescription, producing false non-adherence results.
- ✓ Use a risk calculator tool to educate and demonstrate risk for members.

Numerator Compliance²

Rate 1: SPC Statin - The number of members who had at least one dispensing event for a high-intensity or moderate-intensity statin medication during the measurement year.

Rate 2: SPC 80% Adherence - The number of members who achieved a PDC (proportions of days covered) of at least 80% during the treatment period.

Proportion of Days Covered (PDC):
The number of days the member is covered by at least one statin medication prescription of appropriate intensity, divided by the number of days in the treatment period.

Numerator Codes²

Refer to next page for the list of medications.

Data Collection Method²

Administrative (Claims)



Trillium Percentages/NCQA National Averages¹

SPC	Calendar Year	Trillium	NCQA National Average
Rate 1: SPC Statin	2022	72.5	78.8
	2021	69.7	78.5
Rate 2: SPC 80% Adherence	2022	60.5	69.9
	2021	55.9	70.2

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

¹ Source: ncqa.org/hedis/measures

² Source: HEDIS MY 2024 Tech Specs Manual Vol. 2

AXR Numerator Medications²

Description	Prescription	
High-intensity statin therapy	Amlodipine-atorvastatin 40-80 mg Atorvastatin 40-80 mg Ezetimibe-simvastatin 80 mg	Rosuvastatin 20-40 mg Simvastatin 80 mg
Moderate-intensity statin therapy	Amlodipine-atorvastatin 10-20 mg Atorvastatin 10-20 mg Ezetimibe-simvastatin 20-40 mg Fluvastatin 40-80 mg Lovastatin 40 mg	Pitavastatin 1-4 mg Pravastatin 40-80 mg Rosuvastatin 5-10 mg Simvastatin 20-40 mg

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

¹ Source: [ncqa.org/hedis/measures](https://www.ncqa.org/hedis/measures)

² Source: HEDIS MY 2024 Tech Specs Manual Vol. 2